Pfizer/Pharmacia OTC Motion Sickness Stronghold Could Make FTC Queasy
This article was originally published in The Tan Sheet
Executive Summary
Pfizer's acquisition of Pharmacia likely will draw antitrust regulatory scrutiny to one of the combined firm's smallest product lines - OTC motion sickness tablets
You may also be interested in...
J&J Adds Cortaid, Insight Gets Bonine In Pfizer/Pharmacia Pre-Merger Sell Off
Johnson & Johnson will add Pharmacia's Cortaid OTC anti-itch and rash line to its skin remedies business in one of several divestitures planned to resolve Federal Trade Commission concerns regarding potential monopolies resulting from the merger of Pharmacia and Pfizer
Pfizer/Pharmacia Consumer Product Divestitures Addressing Overlaps – Exec
Overlapping consumer product categories appear to be delaying U.S. and EU regulatory approval of Pfizer's acquisition of Pharmacia
Pfizer/Pharmacia merger
Firms "have substantially narrowed the remaining open matters with both" FTC and European regulatory authorities "to a relatively small number of issues," Pfizer and Pharmacia report Dec. 5. Companies are "confident" transaction will close in first quarter 2003; original target had been year end (1"The Tan Sheet" July 22, 2002, p. 8). Pfizer shareholders voted to approve the deal Dec. 6...